Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMPH Amphastar Pharmaceuticals	$24.19 +0.5%	$27.04	$22.64 ▼ $53.96	$1.26B	0.79	463,854 shs	235,285 shs
ARDX Ardelyx	$5.26 +4.8%	$5.04	$4.02 ▼ $9.33	$1.25B	0.81	4.36 million shs	4.56 million shs
ATYR Atyr PHARMA	$3.35 -2.9%	$3.36	$1.42 ▼ $4.66	$297.68M	0.95	895,518 shs	631,212 shs
DYN Dyne Therapeutics	$11.06 -0.5%	$10.79	$6.36 ▼ $47.45	$1.26B	1.21	1.53 million shs	1.57 million shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMPH Amphastar Pharmaceuticals	0.00%	+3.60%	-14.91%	-34.82%	-41.16%
ARDX Ardelyx	0.00%	+9.13%	+6.69%	-3.84%	-18.07%
ATYR Atyr PHARMA	0.00%	+8.06%	+7.03%	-3.18%	+334,999,900.00%
DYN Dyne Therapeutics	0.00%	+35.37%	-3.41%	-19.09%	-55.28%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMPH Amphastar Pharmaceuticals	4.476 of 5 stars	3.0	3.0	3.7	3.5	4.2	1.3
ARDX Ardelyx	4.4877 of 5 stars	4.5	2.0	4.4	2.3	2.5	0.6
ATYR Atyr PHARMA	2.3367 of 5 stars	3.6	1.0	0.0	1.9	3.3	0.6
DYN Dyne Therapeutics	3.2834 of 5 stars	4.5	1.0	0.0	3.1	4.2	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMPH Amphastar Pharmaceuticals	2.00	Hold	$43.50	79.83% Upside
ARDX Ardelyx	3.00	Buy	$10.61	101.73% Upside
ATYR Atyr PHARMA	3.14	Buy	$18.60	455.22% Upside
DYN Dyne Therapeutics	3.07	Buy	$47.46	329.13% Upside

Current Analyst Ratings Breakdown

Latest ATYR, AMPH, ARDX, and DYN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/10/2025	AMPH Amphastar Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
3/21/2025	AMPH Amphastar Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$36.00 ➝ $32.00
3/21/2025	DYN Dyne Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$18.00 ➝ $17.00
3/17/2025	DYN Dyne Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$46.00 ➝ $46.00
3/17/2025	DYN Dyne Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $50.00
3/14/2025	ATYR Atyr PHARMA	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00 ➝ $35.00
3/12/2025	ARDX Ardelyx	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
3/12/2025	DYN Dyne Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$50.00
3/7/2025	ARDX Ardelyx	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$15.00
3/7/2025	ARDX Ardelyx	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$11.00
3/7/2025	DYN Dyne Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$50.00

(Data available from 4/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMPH Amphastar Pharmaceuticals	$731.97M	1.57	$3.37 per share	7.17	$13.35 per share	1.81
ARDX Ardelyx	$333.62M	3.76	N/A	N/A	$0.73 per share	7.21
ATYR Atyr PHARMA	$235K	1,266.71	N/A	N/A	$1.54 per share	2.18
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	$1.49 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMPH Amphastar Pharmaceuticals	$137.54M	$3.06	8.06	7.35	2.19	21.80%	26.44%	11.89%	5/6/2025 (Estimated)
ARDX Ardelyx	-$39.14M	-$0.16	N/A	16.97	N/A	-11.73%	-24.87%	-10.51%	5/1/2025 (Estimated)
ATYR Atyr PHARMA	-$50.39M	-$0.87	N/A	N/A	N/A	N/A	-79.44%	-59.16%	5/1/2025 (Estimated)
DYN Dyne Therapeutics	-$235.94M	-$3.35	N/A	N/A	N/A	N/A	-57.46%	-51.62%	5/1/2025 (Estimated)

Latest ATYR, AMPH, ARDX, and DYN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	AMPH Amphastar Pharmaceuticals	$0.66	N/A	N/A	N/A	$173.29 million	N/A
5/1/2025	Q1 2025	ARDX Ardelyx	-$0.10	N/A	N/A	N/A	$79.40 million	N/A
5/1/2025	Q1 2025	ATYR Atyr PHARMA	-$0.19	N/A	N/A	N/A	N/A	N/A
5/1/2025	Q1 2025	DYN Dyne Therapeutics	-$0.88	N/A	N/A	N/A	N/A	N/A
3/13/2025	Q4 2024	ATYR Atyr PHARMA	-$0.23	-$0.18	+$0.05	-$0.18	$0.02 million	N/A
3/4/2025	Q4 2024	DYN Dyne Therapeutics	-$0.92	-$0.88	+$0.04	-$0.88	N/A	N/A
2/20/2025	Q4 2024	ARDX Ardelyx	$0.02	$0.02	N/A	$0.02	$111.16 million	$116.13 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMPH Amphastar Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ARDX Ardelyx	N/A	N/A	N/A	N/A	N/A
ATYR Atyr PHARMA	N/A	N/A	N/A	N/A	N/A
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMPH Amphastar Pharmaceuticals	0.82	3.43	2.61
ARDX Ardelyx	0.87	4.58	4.31
ATYR Atyr PHARMA	0.02	5.41	5.41
DYN Dyne Therapeutics	N/A	17.02	17.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMPH Amphastar Pharmaceuticals	65.09%
ARDX Ardelyx	58.92%
ATYR Atyr PHARMA	61.72%
DYN Dyne Therapeutics	96.68%

Insider Ownership

Company	Insider Ownership
AMPH Amphastar Pharmaceuticals	27.10%
ARDX Ardelyx	5.90%
ATYR Atyr PHARMA	3.70%
DYN Dyne Therapeutics	20.77%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMPH Amphastar Pharmaceuticals	1,620	47.50 million	35.05 million	Optionable
ARDX Ardelyx	90	238.36 million	222.88 million	Optionable
ATYR Atyr PHARMA	53	88.86 million	80.84 million	Optionable
DYN Dyne Therapeutics	100	113.63 million	80.63 million	Optionable

ATYR, AMPH, ARDX, and DYN Headlines

Recent News About These Companies

Legal & General Group Plc Has $1.61 Million Stock Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)

April 28 at 3:36 AM | marketbeat.com

Dyne Therapeutics, Inc. (NASDAQ:DYN) Shares Sold by Adage Capital Partners GP L.L.C.

April 27 at 5:59 AM | marketbeat.com

Dyne Therapeutics (DYN) to Release Quarterly Earnings on Thursday

April 26 at 4:02 AM | marketbeat.com

Is Dyne Therapeutics Inc. (NASDAQ:DYN) the Most Promising Small-Cap Stock According to Analysts?

April 26 at 2:44 AM | insidermonkey.com

EC grants orphan drug designation to Dyne Therapeutics’ DMD therapy

April 25 at 8:46 AM | finance.yahoo.com

Dyne Therapeutics stock rises on orphan drug status

April 24, 2025 | au.investing.com

Dyne Therapeutics receives EMA orphan drug designation for DYNE-251

April 24, 2025 | markets.businessinsider.com

Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy

April 24, 2025 | globenewswire.com

Why Dyne Therapeutics, Inc.’s (DYN) Stock Is Up 9.28%

April 23, 2025 | aaii.com

Dyne Therapeutics (NASDAQ:DYN) Shares Up 4% - What's Next?

April 23, 2025 | marketbeat.com

Jump Financial LLC Takes Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)

April 23, 2025 | marketbeat.com

Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost

April 21, 2025 | msn.com

Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 18, 2025 | finanznachrichten.de

Dyne Therapeutics (NASDAQ:DYN) Stock Price Up 6.8% - Here's What Happened

April 17, 2025 | marketbeat.com

Petri Dish: Roche unloads drug to Cambridge biotech, Cue and Boehringer link up

April 17, 2025 | bizjournals.com

Dyne Therapeutics appoints Ranade as CBO, Batra as CSO

April 16, 2025 | markets.businessinsider.com

Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments

April 15, 2025 | globenewswire.com

Fmr LLC Sells 1,029,766 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)

April 15, 2025 | marketbeat.com

Dyne Therapeutics (DYN) Receives a Buy from Piper Sandler

April 14, 2025 | markets.businessinsider.com

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 14, 2025 | globenewswire.com

Federated Hermes Inc. Lowers Stake in Dyne Therapeutics, Inc. (NASDAQ:DYN)

April 11, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATYR, AMPH, ARDX, and DYN Company Descriptions

Amphastar Pharmaceuticals NASDAQ:AMPH

$24.19 +0.12 (+0.50%)

Closing price 04/25/2025 04:00 PM Eastern

Extended Trading

$24.18 -0.01 (-0.02%)

As of 04/25/2025 06:54 PM Eastern

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Ardelyx NASDAQ:ARDX

$5.26 +0.24 (+4.78%)

Closing price 04/25/2025 04:00 PM Eastern

Extended Trading

$5.26 +0.00 (+0.10%)

As of 04/25/2025 07:49 PM Eastern

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Atyr PHARMA NASDAQ:ATYR

$3.35 -0.10 (-2.90%)

Closing price 04/25/2025 04:00 PM Eastern

Extended Trading

$3.36 +0.02 (+0.45%)

As of 04/25/2025 07:59 PM Eastern

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Dyne Therapeutics NASDAQ:DYN

$11.06 -0.05 (-0.45%)

Closing price 04/25/2025 04:00 PM Eastern

Extended Trading

$10.99 -0.07 (-0.62%)

As of 04/25/2025 07:56 PM Eastern

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time